Compare Enveric Biosciences Inc (ENVB) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Charles Schwab Corporation Common Stock — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Charles Schwab Corporation Common Stock trades at $96.87 (market cap $167.52B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 24635.3× Enveric Biosciences Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.32% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Charles Schwab Corporation Common Stock for 85 Days on average.
| ENVB | SCHW | |
|---|---|---|
Market Cap | $6.80M | $167.52B |
Volume | 64,867 | 6,554,126 |
Sector | Health | Financials |
52-Week High | $10.80 | $113.65 |
52-Week Low | $1.27 | $85.35 |
Typical Hold Time | 14 Days | 85 Days |
Enterprise Value | -$1.49M | $153.97B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Charles Schwab (SCHW) trades at $95.58, down 1.26% today, with a bearish technical signal. The stock shows strong fundamentals, with Q2 2026 EPS beating expectations at $1.62 and revenue growth to $23.92B in 2025. Analyst consensus is bullish, with a $119.92 price target, supported by recent news of a secondary listing on the Texas Stock Exchange and AI integration for advisors.
Outlook remains positive due to earnings momentum and market share gains, but risks include competitive pressures and interest rate sensitivity. The stock offers upside from current levels if execution continues, though technical weakness may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
